The Role of an Androgen Receptor Polymorphism in the Clinical Outcome of Patients with Metastatic Prostate Cancer

Publisher： Karger

E-ISSN： 1423-0399|68|1|16-23

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.68, Iss.1, 2002-01, pp. : 16-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Trial of Gallium Nitrate in Patients with Androgen-Metastatic Prostate Cancer

By  

Urologia Internationalis, Vol. 63, Iss. 2, 1999-12 ,pp. : 120-125

Karger

Access to resources Recommend Favorite

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 250-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Effect of Bisphosphonates on Bone Mineral Density in Metastatic Prostate Cancer Patients Who Are Treated with Anti-Androgen Drugs and Radiotherapy

By  

Current Urology, Vol. 7, Iss. 4, 2014-08 ,pp. : 181-184

Karger

Access to resources Recommend Favorite

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer

By  

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3636-3643

John Wiley & Sons Inc

Access to resources Recommend Favorite

The transcriptional programme of the androgen receptor (AR) in prostate cancer

By  

BJU INTERNATIONAL, Vol. 113, Iss. 3, 2014-03 ,pp. : 358-366

John Wiley & Sons Inc

Access to resources Recommend Favorite